Results 11 to 20 of about 1,941 (170)

Differential impact of BTK active site inhibitors on the conformational state of full-length BTK

open access: yeseLife, 2020
Bruton’s tyrosine kinase (BTK) is targeted in the treatment of B-cell disorders including leukemias and lymphomas. Currently approved BTK inhibitors, including Ibrutinib, a first-in-class covalent inhibitor of BTK, bind directly to the kinase active site.
Raji E Joseph   +5 more
doaj   +1 more source

Kvantitatív drámaelemzés és az idő

open access: yesDigitális Bölcsészet, 2023
A kvantitatív drámaelemzés legtöbbször a színművek egészére vonatkozó, statikus mérőszámokból indul ki, továbbá kevés figyelmet fordít az e mérőszámokkal leírt szerkezeti tulajdonságok történeti változásaira. A tanulmányban ezért korábbi eredményeinket,
Botond Szemes, Magyar Magyar
doaj   +1 more source

Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma

open access: yesBiomarker Research, 2022
The advent of BTK inhibitors has changed the treatment of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The first-in-class BTK inhibitor ibrutinib has shown remarkable therapeutic effects and manageable toxicities in ...
Jing Zhang   +3 more
doaj   +1 more source

Effective, safe, and sustained correction of murine XLA using a UCOE-BTK promoter-based lentiviral vector

open access: yesMolecular Therapy: Methods & Clinical Development, 2021
X-linked agammaglobulinemia (XLA) is an immune disorder caused by mutations in Bruton’s tyrosine kinase (BTK). BTK is expressed in B and myeloid cells, and its deficiency results in a lack of mature B cells and protective antibodies.
Brenda J. Seymour   +12 more
doaj   +1 more source

The Immunomodulatory Functions of BTK Inhibition in the Central Nervous System

open access: yesJournal of Inflammation Research, 2022
Tingyu Cao,1 Zengguang Wang,2 Xiaodong Zhu1 1Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, People’s Republic of China; 2Department of Neurosurgery, Tianjin Neurological Institute, Tianjin ...
Cao T, Wang Z, Zhu X
doaj  

Bruton’s Tyrosine Kinase in Neutrophils Is Crucial for Host Defense against Klebsiella pneumoniae

open access: yesJournal of Innate Immunity, 2022
Humans with dysfunctional Bruton’s tyrosine kinase (Btk) are highly susceptible to bacterial infections. Compelling evidence indicates that Btk is essential for B cell-mediated immunity, whereas its role in myeloid cell-mediated immunity against ...
Zhe Liu   +9 more
doaj   +1 more source

The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View

open access: yesJournal of Experimental Pharmacology, 2021
Francesco Paolo Tambaro,1 Danilo De Novellis,1,2 William G Wierda3 1Unità Operativa di Trapianto di Midollo Osseo e Servizio Trasfusionale, Azienda Ospedaliera di Rilievo Nazionale Santobono-Pausilipon, Napoli, Italy; 2Department of Precision Medicine ...
Tambaro FP, De Novellis D, Wierda WG
doaj  

Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies

open access: yesJournal of Hematology & Oncology, 2021
B cell receptor (BCR) signaling is involved in the pathogenesis of B cell malignancies. Activation of BCR signaling promotes the survival and proliferation of malignant B cells.
Danling Gu   +4 more
doaj   +1 more source

Structural Complementarity of Bruton’s Tyrosine Kinase and Its Inhibitors for Implication in B-Cell Malignancies and Autoimmune Diseases

open access: yesPharmaceuticals, 2023
Bruton’s tyrosine kinase (BTK) is a critical component in B-cell receptor (BCR) signaling and is also expressed in haematogenic and innate immune cells. Inhibition of BTK hyperactivity is implicated in B-cell malignancies and autoimmune diseases.
Asim Najmi   +8 more
doaj   +1 more source

Btk inhibitors in atherosclerosis [PDF]

open access: yesBlood, 2018
In this issue of Blood, Busygina et al provide provocative evidence that there is a potential role for Bruton tyrosine kinase (Btk) inhibitors in inhibiting platelet aggregation specifically at the site of unstable atherosclerotic plaques ...
openaire   +2 more sources

Home - About - Disclaimer - Privacy